Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer: A Case Series

被引：6
|
作者：
Sonehara, Kei [1 ]
Tateishi, Kazunari [1 ]
Araki, Taisuke [1 ]
Komatsu, Masamichi [1 ]
Akahane, Jumpei [1 ]
Yamamoto, Hiroshi [1 ]
Hanaoka, Masayuki [1 ]
机构：
[1] Shinshu Univ, Sch Med, Dept Internal Med 1, Matsumoto, Nagano, Japan
来源：
CASE REPORTS IN ONCOLOGY | 2021年 / 14卷 / 03期
关键词：
Adrenal insufficiency; Immune-related adverse events; Non-small cell lung cancer; Pembrolizumab; ASSOCIATION;
D O I：
10.1159/000519597
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Pembrolizumab-induced adrenal insufficiency (AI) is recognized as a rare immune-related adverse event (irAE) that can be fatal if diagnosis is delayed. Clinical features of AI in patients with advanced non-small cell lung cancer (NSCLC) who received pembrolizumab as the firstline treatment were observed. Five out of 49 patients with untreated advanced NSCLC developed AI between April 2017 and February 2021. Of the 5 patients, 4 developed AI with a grade >3 and were hospitalized. The median time of the onset of AI from the start of first-line treatment was 4.63 months. All the patients improved after corticosteroid replacement therapy. The efficacy of treatment was complete response in 1 patient and partial response in 4 patients. Median progression-free survival was 37.7 months, and overall survival had not been reached. This case series revealed the efficacy of immunotherapy in AI as an irAE. (C) 2021 The Author(s). Published by S. Karger AG, Basel
引用
收藏
页码：1561 / 1566
页数：6
相关论文
共 50 条
  • [21] Non-small cell lung cancer transdifferentiation into small cell lung cancer: A case series
    Ahmed, Tahreem
    Vial, Macarena R.
    Ost, David
    Stewart, John
    Hasan, Muhammad A.
    Grosu, Horiana B.
    LUNG CANCER, 2018, 122 : 220 - 223
  • [22] Pembrolizumab combined with stereotactic body radiotherapy in a patient with human immunodeficiency virus and advanced non-small cell lung cancer: A case report
    Li D.
    He C.
    Xia Y.
    Du Y.
    Zhang J.
    Journal of Medical Case Reports, 12 (1)
  • [23] Pembrolizumab-induced aseptic meningitis in a patient with non-small cell lung cancer: A case report and literature review of aseptic meningitis as an immune-related adverse event
    Inui, Genki
    Funaki, Yoshihiro
    Makino, Haruhiko
    Touge, Hirokazu
    Arai, Katsunori
    Kuroda, Keisuke
    Hirayama, Yuuki
    Kato, Ryohei
    Nonaka, Takafumi
    Yamane, Kohei
    Teruya, Yasuhiko
    Sueda, Yuriko
    Sakamoto, Tomohiro
    Yamaguchi, Kosuke
    Kodani, Masahiro
    Kawase, Shinya
    Umekita, Yoshihisa
    Horie, Yasushi
    Nosaka, Kanae
    Yamasaki, Akira
    MOLECULAR AND CLINICAL ONCOLOGY, 2022, 17 (01)
  • [24] TROPION-Lung08: Datopotamab Deruxtecan Plus Pembrolizumab in Untreated Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC)
    Zhou, C.
    Levy, B. P.
    Sands, J.
    Parakh, S.
    Sugawara, S.
    Syrigos, K.
    Ahn, J. S.
    Zhao, M.
    Lin, C. -C.
    Felip, E.
    Cappuzzo, F.
    Reck, M.
    Yang, J. C. H.
    Joseph, R.
    Rawat, S.
    Xie, J.
    Okamoto, I.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S327 - S328
  • [25] Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date
    Vachhani, Pankit
    Chen, Hongbin
    ONCOTARGETS AND THERAPY, 2016, 9 : 5855 - 5866
  • [26] Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol
    Liu Yan'e
    Zhang Jie
    Yin Zhongnan
    Zhu Xiang
    Xue Lixiang
    Cao Baoshan
    THORACIC CANCER, 2020, 11 (07) : 2023 - 2030
  • [27] Immunotherapy in Advanced Non-Small Cell Lung Cancer
    Huang, Joy
    Reckamp, Karen L.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 41 (03) : 400 - 408
  • [28] Pembrolizumab in advanced non-small cell lung cancer: safety implications of dose adjustments
    Gower, Arjan
    Garon, Edward B.
    TRANSLATIONAL CANCER RESEARCH, 2022,
  • [29] Pembrolizumab in Combination with Chemotherapy as First-Line Treatment of Advanced Non-Small Cell Lung Cancer
    Jahan, N.
    Swarup, S.
    Sultan, A.
    Naing, T.
    Mogollon-Duffo, F.
    Ball, S.
    Tun, A.
    Htut, T.
    Dash, A.
    D'Cunha, N.
    Hardwicke, F.
    Awasthi, S.
    Tijani, L.
    Thein, K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S917 - S918
  • [30] Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases
    Zhang, Michael
    Rodrigues, Adrian J.
    Pollom, Erqi L.
    Gibbs, Iris C.
    Soltys, Scott G.
    Hancock, Steven L.
    Neal, Joel W.
    Padda, Sukhmani K.
    Ramchandran, Kavitha J.
    Wakelee, Heather A.
    Chang, Steven D.
    Lim, Michael
    Hayden Gephart, Melanie
    Li, Gordon
    JOURNAL OF NEURO-ONCOLOGY, 2021, 152 (01) : 125 - 134
12345